П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated avarage burden

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person [*] <u>Brady Todd C</u>			2. Issuer Name and Ticker or Trading Symbol Oncobiologics, Inc. [ONS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u></u>				X	Director	10% Owner			
(Last) C/O ONCOBIO		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/09/2016		Officer (give title below)	Other (specify below)			
7 CLARKE DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	(Check Applicable				
(Street)				X	Form filed by One Repor	ting Person			
CRANBURY	NJ	08521			Form filed by More than Person	One Reporting			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transa Code (action	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1str.			5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial
		(Month/Day/Year)	8) Code	v	Amount	(A) or (D)	Price	Owned Following Reported Transaction(s) (Instr. 3 and 4)	(l) (Instr. 4)	Ownership (Instr. 4)
Restricted Stock Units ⁽¹⁾	11/09/2016		С		28,985(2)(3)	D	\$0	28,985	D	
Common Stock	11/09/2016		М		28,985	A	(2)	153,288	D	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)	Instr.	of E		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Granted pursuant to the Issuer's 2015 Equity Incentive Plan.

2. Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock.

3. The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering ("IPO"), subject to continued service through such event) and (b) time-based vesting restrictions (50% of the RSUs will satisfy the time-based vesting restrictions on each of the third and fourth anniversaries of July 11, 2013, subject to continued service through such dates). In addition, 100% of the RSUs will satisfy the time-based vesting restrictions of a change of control, subject to continued service through such dates).

Remarks:

/s/ Lawrence Kenyon,

Attorney-in-Fact

11/14/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.